KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer
详细信息 查看全文
- 作者：Á ; dá ; m Nagy ; Lőrinc Sá ; ndor Pongor ; Andrá ; s Szabó ; Mariacarmela Santarpia and Balá ; zs Győrffy
- 刊名：International Journal of Cancer
- 出版年：2017
- 出版时间：15 February 2017
- 年：2017
- 卷：140
- 期：4
- 页码：930-937
- 全文大小：380K
- ISSN：1097-0215
文摘
KRAS is the most frequently mutated oncogene in non-small cell lung cancer (NSCLC). However, the prognostic role of KRAS mutation status in NSCLC still remains controversial. We hypothesize that the expression changes of genes affected by KRAS mutation status will have the most prominent effect and could be used as a prognostic signature in lung cancer.